<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346902</url>
  </required_header>
  <id_info>
    <org_study_id>EB001-SR201</org_study_id>
    <nct_id>NCT03346902</nct_id>
  </id_info>
  <brief_title>Study of EB-001 in Facial Scar Reduction</brief_title>
  <official_title>A Phase 2 Study to Evaluate Safety and Efficacy of EB-001 Injections in Facial Scar Reduction After Undergoing Mohs Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bonti, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bonti, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of EB-001 in improving wound healing and&#xD;
      reducing scar formation in patients undergoing Mohs surgery for skin lesions in the forehead&#xD;
      area following a single treatment of EB-001 when injected into the muscles underlying the&#xD;
      incision area.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and efficacy of EB-001 in improving wound healing and&#xD;
      reducing scar formation in patients undergoing Mohs surgery for skin lesions in the forehead&#xD;
      area following a single treatment of EB-001 when injected into the muscles underlying the&#xD;
      incision area.&#xD;
&#xD;
      The safety objective is to determine the safety and tolerability of single treatment of&#xD;
      EB-001 when injected into facial muscles underlying a surgical wound during Mohs surgery.&#xD;
&#xD;
      The efficacy objective is to evaluate the efficacy of a single treatment of EB-001 when&#xD;
      injected into the facial muscles (frontalis) underlying the surgical wound in improving wound&#xD;
      healing, and reducing scar formation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Actual">October 8, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best))</measure>
    <time_frame>Day 30</time_frame>
    <description>Assessment of change in Visual Analog Scale score (values from 0 (worst) to 10 (best)) from day of surgery to Day 30. Percentage of subjects reporting an improvement in Visual Analog Scale score.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Mohs Surgery</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: : Placebo: 0.9% Sodium Chloride Injection&#xD;
Injection of Placebo into area of scarring (forehead)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB001</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: EB-001 Injection of EB-001 into area of scarring (forehead)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EB-001</intervention_name>
    <description>Injection of EB-001 into area of scarring (forehead)</description>
    <arm_group_label>EB001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Sodium Chloride Injection</intervention_name>
    <description>Injection of Saline into area of scarring (forehead)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between 18 and 75 years of age, inclusive&#xD;
&#xD;
          2. Subject in good health, or with stable treated medical condition, as determined by the&#xD;
             investigator.&#xD;
&#xD;
          3. Scheduled to undergo Mohs surgery to remove a single skin lesion in the forehead. This&#xD;
             could be&#xD;
&#xD;
               1. Basal Cell Carcinoma&#xD;
&#xD;
               2. Squamous Cell Carcinoma (non-metastatic)&#xD;
&#xD;
               3. Other suitable lesions according to the investigator opinion&#xD;
&#xD;
          4. Lesion closure size at least 2 cm in length&#xD;
&#xD;
          5. Women of non-childbearing potential must be postmenopausal (at least 12 consecutive&#xD;
             months of amenorrhea)&#xD;
&#xD;
          6. Women of childbearing potential must not be pregnant, lactating, or planning to become&#xD;
             pregnant during the study&#xD;
&#xD;
          7. Women of childbearing potential agreeing to use either&#xD;
&#xD;
               1. a highly effective method of contraception with failures rates less than 1% per&#xD;
                  year such as implant, intrauterine device (IUD), or sterilization from the day of&#xD;
                  dosing for 3 months (subjects who underwent sterilization must have initiated the&#xD;
                  procedure at least 3 months prior to the day of dosing) or&#xD;
&#xD;
               2. dual methods of contraception with overall failures rates less than 1% per year&#xD;
                  such as injectable, pill, patch, ring, and diaphragm from the day of dosing for 3&#xD;
                  months (subjects using oral contraception must have initiated treatment at least&#xD;
                  2 months prior to the day of dosing)&#xD;
&#xD;
          8. Willing and able to complete and comply with procedures, protocol requirements and&#xD;
             instructions, which includes completion of all required visits&#xD;
&#xD;
          9. Willing and able to sign and date IRB-approved informed consent&#xD;
&#xD;
         10. Able to speak, read, and understand the language of the informed consent form (ICF)&#xD;
             and study questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast feeding, or planning a pregnancy&#xD;
&#xD;
          2. Body weight less than 50 kg (110 pounds)&#xD;
&#xD;
          3. Reported use of any botulinum toxin of any serotype within last 6 months before study&#xD;
             drug administration&#xD;
&#xD;
          4. Anticipated use of any botulinum toxin of any serotype during the study&#xD;
&#xD;
          5. Known hypersensitivity to any botulinum toxin serotype&#xD;
&#xD;
          6. Known allergy or sensitivity to any of the components of the study treatments, or any&#xD;
             materials used in the study procedures&#xD;
&#xD;
          7. Aminoglycoside intake within 48 hours prior to or during surgery&#xD;
&#xD;
          8. Pre-existing disorders of the neuromuscular junction (myasthenia gravis, Eaton-Lambert&#xD;
             syndrome, or amyotrophic lateral Sclerosis)&#xD;
&#xD;
          9. Any uncontrolled medical condition that in opinion of investigator, puts subject at&#xD;
             undue safety risk&#xD;
&#xD;
         10. Any clinically significant psychiatric condition that, in opinion of investigator, may&#xD;
             interfere with study assessments or protocol compliance&#xD;
&#xD;
         11. Any cosmetic procedure, laser resurfacing treatment, or retinoid therapy in the&#xD;
             forehead area in the past 30 days before study drug administration&#xD;
&#xD;
         12. Any eyebrow or eyelid ptosis at baseline as determined by the Investigator&#xD;
&#xD;
         13. History of hypertrophic scars or keloid formation or other wound abnormalities as&#xD;
             assessed by the investigator&#xD;
&#xD;
         14. History of alcohol or drug abuse in the last 3 years, based on investigator judgement&#xD;
&#xD;
         15. User or former user of nicotine-containing products, as follows:&#xD;
&#xD;
               1. including but not limited to cigarettes, cigars, and chewing or dipping tobacco)&#xD;
                  who stopped use or consumption (i.e., smoking, chewing, or pinching) of these&#xD;
                  nicotine-containing products less than 1 year before study drug administration,&#xD;
                  or&#xD;
&#xD;
               2. topical or oral nicotine preparations for smoking cessation within the past 90&#xD;
                  days before study drug administration&#xD;
&#xD;
         16. Anticipated need for surgery or overnight hospitalization during the study&#xD;
&#xD;
         17. Current enrollment in an investigational drug or device study or participation in such&#xD;
             a study within 30 days or 5 half-lives of the drug, whichever is longer, of entry into&#xD;
             this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Earvin Liang</last_name>
    <role>Study Director</role>
    <affiliation>Bonti, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <results_first_submitted>October 17, 2018</results_first_submitted>
  <results_first_submitted_qc>November 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 14, 2018</results_first_posted>
  <last_update_submitted>December 14, 2018</last_update_submitted>
  <last_update_submitted_qc>December 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03346902/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>0.9% Sodium Chloride Injection: Single Injection of Saline into area of scarring (forehead)</description>
        </group>
        <group group_id="P2">
          <title>EB001</title>
          <description>EB-001: Single Injection (0.5mL total) of EB-001 into area of scarring (forehead).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>0.9% Sodium Chloride Injection: Single Injection of Saline into area of scarring (forehead)</description>
        </group>
        <group group_id="B2">
          <title>EB001</title>
          <description>EB-001: Single Injection (0.5mL total) of EB-001 into area of scarring (forehead)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="60" upper_limit="75"/>
                    <measurement group_id="B2" value="59" lower_limit="34" upper_limit="72"/>
                    <measurement group_id="B3" value="62" lower_limit="34" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.28" spread="25.528"/>
                    <measurement group_id="B2" value="79.94" spread="19.352"/>
                    <measurement group_id="B3" value="82.38" spread="21.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best))</title>
        <description>Assessment of change in Visual Analog Scale score (values from 0 (worst) to 10 (best)) from day of surgery to Day 30. Percentage of subjects reporting an improvement in Visual Analog Scale score.</description>
        <time_frame>Day 30</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride Injection: Single Injection of Saline into area of scarring (forehead)</description>
          </group>
          <group group_id="O2">
            <title>EB001</title>
            <description>EB-001: Single Injection (0.5mL total) of EB-001 into area of scarring (forehead)</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best))</title>
          <description>Assessment of change in Visual Analog Scale score (values from 0 (worst) to 10 (best)) from day of surgery to Day 30. Percentage of subjects reporting an improvement in Visual Analog Scale score.</description>
          <population>mITT</population>
          <units>Percentage reporting improvement</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>0.9% Sodium Chloride Injection: Single Injection of Saline into area of scarring (forehead)</description>
        </group>
        <group group_id="E2">
          <title>EB001</title>
          <description>EB-001: Single Injection (0.5mL total) of EB-001 into area of scarring (forehead)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Asymmetry in facial features as a result of the temporal nerve being affected during the Mohs Surger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wajdie Ahmad</name_or_title>
      <organization>Bonti</organization>
      <phone>9493796569 ext 9493796569</phone>
      <email>wajdie@bonti.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

